ETON - Eton Pharmaceuticals Inc Stock Price, Fair Value and News

$12.51-0.06 (-0.48%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ETON Price Action

Last 7 days

1.8%

Last 30 days

20.5%

Last 90 days

131.9%

Trailing 12 Months

177.5%

ETON RSI Chart

ETON Valuation

Market Cap

323.2M

Price/Earnings (Trailing)

-58.97

Price/Sales (Trailing)

9.32

EV/EBITDA

-87.53

Price/Free Cashflow

153.4

ETON Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ETON Fundamentals

ETON Revenue

Revenue (TTM)

34.7M

Rev. Growth (Yr)

46.9%

Rev. Growth (Qtr)

13.78%

ETON Earnings

Earnings (TTM)

-5.5M

Earnings Growth (Yr)

208.29%

Earnings Growth (Qtr)

120.62%

ETON Profitability

Operating Margin

92.44%

EBT Margin

-15.30%

Return on Equity

-34.3%

Return on Assets

-15.29%

Free Cashflow Yield

0.65%

ETON Investor Care

Shares Dilution (1Y)

0.69%

Diluted EPS (TTM)

-0.15

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	34.3M	31.4M	34.7M	0
2023	24.4M	29.0M	32.8M	31.6M
2022	12.1M	16.4M	18.8M	21.3M
2021	9.1M	13.3M	17.6M	21.8M
2020	558.0K	578.0K	0	4.8M
2019	385.5K	607.0K	582.0K	959.0K
2018	0	0	0	164.0K
2017	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Eton Pharmaceuticals Inc

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and dehydrated alcohol injection to treat methanol poisoning. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis; Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis; EPRONTIA, a liquid formulation of topiramate; ZONISADE, a liquid formulation of zonisamide for the treatment of partial seizures in patients with epilepsy; and Lamotrigine for Oral Suspension for the treatment of epilepsy. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

CEO	Mr. Sean E. Brynjelsen
WEBSITE	etonpharma.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	28

Eton Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Eton Pharmaceuticals Inc? What does ETON stand for in stocks?

ETON is the stock ticker symbol of Eton Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eton Pharmaceuticals Inc (ETON)?

As of Fri Dec 20 2024, market cap of Eton Pharmaceuticals Inc is 324.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ETON stock?

You can check ETON's fair value in chart for subscribers.

Is Eton Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ETON is over valued or under valued. Whether Eton Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Eton Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ETON.

What is Eton Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, ETON's PE ratio (Price to Earnings) is -59.25 and Price to Sales (PS) ratio is 9.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ETON PE ratio will change depending on the future growth rate expectations of investors.